Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Retained Earnings (2018 - 2025)

Historic Retained Earnings for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to -$34.4 million.

  • China SXT Pharmaceuticals' Retained Earnings fell 3476.45% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.4 million, marking a year-over-year decrease of 3476.45%. This contributed to the annual value of -$28.0 million for FY2025, which is 1336.88% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Retained Earnings stood at -$34.4 million for Q3 2025, which was down 3476.45% from -$28.0 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Retained Earnings high stood at -$10.0 million for Q1 2021, and its period low was -$34.4 million during Q3 2025.
  • For the 5-year period, China SXT Pharmaceuticals' Retained Earnings averaged around -$22.1 million, with its median value being -$23.2 million (2023).
  • In the last 5 years, China SXT Pharmaceuticals' Retained Earnings plummeted by 12401.83% in 2021 and then surged by 1850.91% in 2024.
  • China SXT Pharmaceuticals' Retained Earnings (Quarter) stood at -$13.0 million in 2021, then tumbled by 31.73% to -$17.2 million in 2022, then plummeted by 82.21% to -$31.3 million in 2023, then grew by 18.51% to -$25.5 million in 2024, then tumbled by 34.76% to -$34.4 million in 2025.
  • Its Retained Earnings stands at -$34.4 million for Q3 2025, versus -$28.0 million for Q1 2025 and -$25.5 million for Q3 2024.